Ethical and Legal Issues in Whole General Diagnostics

OF MOLDOVEAR OF TOAGEEA CORNER 2010 T. T. T. T. RAMATION AGET S TREE AND AN BE ENORATION AGOAA CAGG RCH RCER TCCAACA ! CERNCA AGAGGAAGG DISORDER PATIENC A SIGNIFICAN OTHER こえんでみからし Timothy Caulfield

Timothy Caulfield

University of Alberta







Random Selection of Issue (that need work) **DTC Testing and Popular Culture** Impact on Health Systems **Incidental Findings/Return of Results Patent Problems Family Consent**

"Random <u>Numbers (#1)</u>" 2002, by Mel Bochner




Massive challenge.

Few NEW issues.

(Just a bigger mountain)

Few answers.



What price personal genome exploration?

NEWS Accessible genomes move closer

Com

Exciting as it is, the prespect as our multiple genomes patheness, mass dauting data of the patheness are taken than a construction of the Genomess and the patheness of the Genomess and the second all y lock to catalogue the can-or, an actue myst what these multiplication areas, Mardue group had o seend marking and abased of variations areas and abased of variations.

Control of direct-to-consumer genetic testing

The human genome project has spawned a new commercial field, molecular diagnostics. Some companies charge as much as US\$350000 to scan a person's entire genome to forecast disease risk. Other companies claim to be able to diagnose and determine the most effective treatment for people who are at high risk of developing specific diseases. Medical groups have expressed doubte about

of companies marketing genetic tests without acceptable proof of clinical reliability.

Last week, the FDA made a positive move. A warning letter sent to the Laboratory Corporation of America, the nation's second-largest clinical laboratory company, states that the company's OvaSure test is illegally marketed and

blic-health risk. Introduced in June, proteins in blood to assess whether varian cancer. Because the test was

PRINTER-PRIENOLY FORMAT SPONSORED BY

training to be an astronaut.

variant that raises his risk of

th risk of breast cancer, which

NOW PLAYING

Radoje Drmanac, et al., "Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays" Science (2010) -\$4500 sequences!

EDITORIAL

My genome. So what?

TEL Party "I"

Research is needed into information, and into p

www.nature.com/nature

uman genome research anticipated, the speed disease has quickened, and fed back to them in electro groups reveal individual genor. page 53), and of a Han Chinese each - a fraction of that of the editions.

The age of personal genomes is

Peek at the Experts' Conetic Secrets "Genome sequencing of large numbers of individuals promises to advance the understanding, treatment, and prevention of human diseases, among other applications."

My genome. By AMY HARMO

s the first conference on personal genomes open this month at Cold Spring Harbor Laboratory in New York, some present were wondering whether the event was a little premature. After all, only four people's genomes have so far been fully sequenced and assembled, and it's still quite difficult to interpret the genetic variation found in them (see page 1014). But the participants soon began to realize that, in one sense, the meeting was overdue. Increasingly, private companies are offering personal genome scans and genetic tests for sale — and consumers are buying them. Meanwhile, some scientists earlier this week made public parts of their genetic and medical data through the Personal Genome Project,

entific and means the Mean Hortz Amis - use Who Cares to visit a public Web site, www.personalgenomes.org. The three ing, the public desperately wants help in making such a stew of content. Part of the problem is the information overload provided by the public overload ground by the three steries and other questions - and, if all goes according to part of the problem is the information overload provided by the public web site, www.personalgenomes.org. The three three steries are consumers can point their browsers to a slew of content.

which can come from both trusted sources and charlatans. And in the age of e-mail whisper campaigns, lies can proliferate, opinions can replace facts, and experts are no longer trusted to know the truth.

put the genie back in the bottle."

Invention Of the Year

Your genome used to be a closed book. Now a simple, affordable test can shed new light on everything from your intelligence to your biggest health risks. Say hello to your DNAif you dare

What Your Gene Test Can Tell You




13% chance of developing braset cancer

Probably Instance Informati

BMC Medical Ethics

BioMed Cen



lives? Will this drive

interest policy



UPDATE: 23andMe Says LabCorp Incorrectly Processed 96 Samples, Mixing up Customer Data

http://www.genomeweb.com//node/942439?hq_e=el&hq_m=739114&hq_l=2& hq v=42c8152690

June 09, 2010

By Turna Ray

This article has been updated from a previous version to include customer comments, as well as comments from 23 and Me about how the company is managing the problem.

23andMe informed its customers last week that the contracted laboratory where saliva samples are analyzed "incorrectly processed" many of them.

F Genetic on Ret between the drugstore and Pathway Genomics , a San Diego company that markets at-home

Databanks and Privacy

Protection Norms

Commissioner of Canada

1e, 2

March 2010

 $\mathcal{O}^{\mathcal{O}}$

or benign?

Analysis of Privacy Seant impact on "Overall, predispositional genetic testing has no Policies and Practices of psychological outcomes, little effect on behavi Direct-to-Consumer Direct-to-consumer genetic testing: good, bad "" Genetic Testing cholo/ Companies: Private Sector

T Caulfield^{ab}, NM Ries^{b,c},

B Wilson⁹

PN Ray^{d,e}, C Shuman¹ and

Caulfield T, Ries NM, Ray PN, Shuman C, Wilson B, Direct-to-consumer genetic testing: good, bad of benigh: Clin Genet 2010: 77: 101–105. © John Wiley & Sons A/S, 2009 genotyping result with Alzheimer's disease did not resu psychological r

Report funded by the Office of the Privacy Green et al., NEJM, 2009

Health Law Institute, University of Alberta personal genetic nearth disposition results for more than 70 nearth conditions, including pharmacogenetics (prescription medication response), propensity for complex disease,

Interest??:Canadian DTC Survey

Ries, Hyde-Lay, Caulfield, 2010

Table 4: Factors that Influence Interest in Genetic Testing

	No effect			Strong effect	
	1	2	3	4	5
Availability of treatment	16.1	5	17.7	19.6	41.6
Curiosity	41	14	21.6	11	12.5
Reproductive decisions	44.4	7	17.7	12.4	18.5
Fear of discrimination	32.9	6.4	15.4	12.9	32.4
Healthy lifestyle choices	24.3	7.5	22.1	22.3	23.8
Departed as nerespitants of all respondents					

Reported as percentage of all respondents.

Impact on Health Systems

CAACCCTGG CORT TGAGOGAGOA O MADLECULAR OF AGCCA CORRECT RASA TICK AG S 30 C C ENERATION ABOAA CAGOG Sec. 68 RC H CEARCA AGAGGAA DISORDER PATIENC A SIGNIFICAN OTHER 5 TITOTAWOLE THUT WAR IN

Impact on healthcare costs?

74% report they would use it to gain disease knowledge. 34% consider the information to be a medical diagnosis. 78% would ask their provisician for help interpreting test results.

rofessional responsibility.

The American Journal of Bioethics, Copyright © Taylor & Francis (1990) ISSN: 1526-5161 print / 1536-/072 DOI: 10.1080/152651609029

Target Article

Social So

Amy L. McGuire, Conter for Medial Ethics and Health Policy, Baylor College of Medicine Christina M. Liaz, Center for Medial Ethics and Health Policy, Baylor College of Medicine

Tao Wang, Lester & Sue Smith Breast Center, Baylor College of Medicine **Susan G. Hilsenbeck**, Lester & Sue Smith Breast Center, Baylor College of Medicine

Personal Genomics Research

CCCTGG COR

TOUGH ISSUES!

CEAT CE FUTURES

Return of Results and Incidental Findings?

Do they want results?

November 2008 · Vol. 10 · No. 11

article

Subjects matter: a survey of public opinions large genetic cohort study

Therapeutic misperception? David Kaufman. PhD. Iuli Murphy. MS. Ioan Scott. MS. CGC. and Kathy Hudson. groups; variation in influences of the three factors on willingness was obg exists in the general public for a large national cohort study. Providing individual research results is a strong motivation to participate; compensating participants \$200 may increase participation a similar amount. Incentives, recruitment, and return of results could be tailored to demographics groups' interests. Genet Med 2008:10(11): 831-839.

Legal obligation? Interest in results driven by pop culture representations? What do you return?



The Diploid Genome Sequence of J. Craig

- Managing Incidental Findings in
- ar Human Subjects
- a Research:
- en Analysis and
- T Recomm ndations
- tc Susan M. Wolf,
 - Frances P. Lawrenz, Charles A. Nelson,
- Jeffrey P. Kahn, Mildred K. Cho, Ellen Wright Clayton,
- Joel G. Fletcher,
 - Michael K. Georgieff, Dale Hammerschmidt, Kathy Hudson, Judy Illes, Vivek Kapur, Moira A. Keane, Barbara A. Koenig, Bonnie S. LeRoy, Elizabeth G. McFarland, Jordan Paradise, Lisa S. Parker, Sharon F. Terry, Brian Van Ness, and Benjamin S. Wilfond


, Personal ects should have s, approved by w entity, for ndings (incidental Perspectives Research Ethics Recommendations Provide a constraint of the second and the second

Principal Control See Oncludes that researchers have an obligation to address the possibility of discovering IFs not only in their protocol and communications with the IRB, but also in their consent forms and communications with those being recruited to the study and research participants.

rnal.pbio.0050254.sd001, Levy et al, 2007

Family Consent?

51 C 63 P 6 CAACCCTGG CORT TGAGOCAGOA O MADLECULAR OF SCCA CORNET RAMATICAL ALS 15 O C C ENGRATION AGOAAG CAGO 20.00 RCH BECT S CENACA AGAGGAA DISORDER PATIENC A SIGNIFICAN OTHER TELO TANGLES ロードしている正分




Patent Problems?


CCCTAG COR

TOUGH ISSUES!

COM A AGGO DISOLOUR PATIENCE STITTA SIGNIFICANTIN UVISHES OTHER TH THOTCATETO TANOLO GEATES FUTURES

> The access and "anticommons" debate





DTC – driving regulatory debate (Harm?; How much interest?)
Impact of pop culture?
Impact on health systems?
Incidental findings/ Return of results- fit with norms?
Impact of patents?
Family consent?

Thank you!

•Amy Zarzeczny, Robyn Hyde-Lay, Ubaka Ogbogu, Nola Ries, Tania Bubela, the AHFMR, and the HLI research team.

